AGAna Julia Pereira Santinho Gomes

Ana Julia Pereira Santinho Gomes

*This is an algorithmically generated author record based on publicly available information.

Ana Julia Pereira Santinho Gomes has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metformin hydrochloride extended-release tablets: perception of the occurrence of gastrointestinal adverse events and biopharmaceutical evaluation

    by Angelo Elias Meri Junior, Adrila David Meri, Karina Aparecida Resende, Maria Isabel C. Miranda, Mirelly O.S. Souza, André O. Baldoni, Cristina Sanches, Ana Julia P.S. Gomes, Whocely Victor Castro

    Diarrhea is a common adverse event at the beginning of metformin hydrochloride use. Extended-release (XR) tablets are an alternative for patients intolerant to the immediate-release formulation. This study evaluated the perception of gastrointestinal adverse events (GAE), quality, and dissolution behavior between reference (R) and generic (G) XR formulations. A prospective cohort study recorded diarrhea, abdominal discomfort, and impact on daily activities using a perception form. R and G were analyzed for quality and dissolution behavior. Among 29 patients, 16 used R (55.2%) and 13 G (44.8%). Both groups presented GAE (diarrhea: R= 8, G= 8; abdominal discomfort: R= 9, G= 7). BMI was significantly associated with the occurrence of GAE regardless of the medications studied. All samples met pharmacopoeial quality standards. The Higuchi model best described the dissolution kinetics of R, and Peppas-Sahlin for G. The dissolution profiles were similar (F2= 67), although the dissolution efficiency differed by more than 10%. Our findings reinforce the interchangeability between reference and generic medicines, providing an effective option for patients with type II diabetes mellitus. This strengthens the principles of the National Generic Medicines Policy in Brazil, contributing to the sustainability of the healthcare system and the democratization of access to essential medicines.

  • Open Access

    Study of a tooth gel formulation for hygiene and oral sequelae management in irradiated patients

    by Ana Carolina Lara Ribeiro, Marina Goulart da Silva, Ana Gabriela Reis Solano, Harley da Silva Tavares, Ana Julia Pereira Santinho Gomes

    Cervical-facial radiotherapy causes innumerable sequelae, being systemic or restricted to the oral environment. The oral mucosa of these patients is profoundly compromised by radiotherapeutic treatment with or without chemotherapy, presenting several complications. Dentifrices containing sodium lauryl sulfate cause damage, as they lead to dryness of the mucosa. The objective of this work was to develop a dentifrice capable of minimizing xerostomia related to a lower abrasive effect, which was intended for hygiene, prevention of caries, control of dental biofilm, and tooth sensitivity in cancer patients. The qualitative composition and physicochemical characteristics of ten dentifrices were analyzed, which enabled the preparation of the proposed formulation (PF) that was analyzed periodically for 180 days. The quantitative analysis of spreadability not only indicated favorable behavior of the PF in relation to the packaging and storage conditions but also revealed the need to raise the propylene glycol concentration in the PF to avoid the occurrence of syneresis after 60 days. Furthermore, pH data showed that the PF is compatible with the pH of oral homeostasis thus avoiding the occurrence of dental demineralization. It is suggested that the PF has a singular composition and physicochemical quality to be used as a suitable dentifrice for patients undergoing anticancer therapy.


  • Open Access

    Evaluation of the frequency of gastrointestinal adverse events associated with the use of prolonged-release metformin hydrochloride

    by Karina Aparecida Resende, Angelo Elias Meri Junior, Maria Isabel Campos Miranda, Adrila David Meri, Flavio Marques Lopes, Adrielle Pieve De Castro, Wanderley José Mantovani Bittencourt, Cristina Sanches, Ana Julia Pereira Santinho Gomes, Whocely Victor De Castro

    Diabetes mellitus is defined by hyperglycemia resulting from impaired insulin action or distress, or both. Metformin is widely prescribed to control the disease and the most common adverse events caused by its use are diarrhea, nausea and/or abdominal discomfort. We evaluated the frequency profile of gastrointestinal adverse events associated with the use of metformin. This is a cross-sectional observational study, in which the occurrence of diarrhea in patients with type 2 diabetes mellitus who started treatment with metformin hydrochloride at a dose of 500 mg of prolonged release was reported. 12 (41.37%) participants were male and 17 (58.62%) were female. Diarrhea was present (n=16) in more than half of the patients (55.2%) who used the drug. Patients had an average of 12 episodes of diarrhea per month. There was also the presence of abdominal discomfort (n=7), in which 24.1% reported being very high. The study showed that the extended-release drug metformin hydrochloride 500 mg can cause gastrointestinal adverse events at the start of treatment and lasts for approximately twelve days.


  • Open Access

    Effectiveness of topically applied chamomile in the treatment of oral mucositis: a literature review

    by Heitor Tadeu Cardoso Santos, Mairon César Coimbra, Angelo Elias Meri Junior, Ana Julia Pereira Santinho Gomes

    Oral mucositis (OM) is one of the main adverse events observed during the treatment of neoplasms, especially in relation to head and neck (H&N) cancer. Complications, initially non-infectious of OM, can significantly compromise the chosen therapy, extend the hospitalization period and decrease the quality of life of patients with H&N cancer. Therefore, the present work presents a narrative review that gathers, presents and discusses studies on the relationship between the topical application of chamomile-based pharmaceutical products and the treatment of oral mucositis, with an emphasis on its effectiveness. A literature search was conducted in August 2021 using PubMed, Scielo and LILACS. From literature search was identified 869 papers, of which 06 were selected to answer the guiding question of this study. Finally, it could be seen that chamomile has great potential to help manage OM, as well as other oral complications, especially in cases of patients undergoing H&N cancer treatments using radiotherapy. Furthermore, formulations containing chamomile have been shown to be effective in slowing the progression of OM grades. However, it is necessary to evaluate in each formulation, the possible impacts of each pharmaceutical adjuvant, as well as the adverse events capable of increasing pharmacotherapeutic adherence.


  • A systematic review of instruments measuring grief after perinatal loss and factors associated with grief reactions

    by M.S. Setubal, R. Bolibio, R.C. Jesus, G.G. Benute, M.A. Gibelli, N. Bertolassi, T. Barbosa, A. Gomes, F. Figueiredo, R. Ferreira, et al.

    Objective: Expectant parents who live through perinatal loss experience intense grief, which is not always acknowledged or accepted. A screening tool to detect bereaved parents’ grief reactions can guide professionals, including perinatal palliative care teams, to provide follow-up for those in need. This review's goal is to identify and synthesize the international published literature on existent instruments specifically measuring the grieving process after any perinatal loss and to identify factors that could moderate grief reactions.Method: Systematic review (PROSPERO # CRD42018092555) with critical synthesis. PUBMED, Cochrane, and PsycINFO databases were searched in English language articles using the keywords “perinatal” AND (“grief” OR “bereavement” OR mourning) AND (“scale” OR “questionnaire” OR “measure” OR “assessment”) up to May 2018. Eligibility criteria included every study using a measure to assess perinatal grief after all kinds of perinatal losses, including validations and translations to other languages and interventions designed to alleviate grief symptoms.Results: A total of 67 papers met inclusion criteria. Seven instruments measuring perinatal grief published between 1984 and 2002 are described. The Perinatal Grief Scale (PGS) was used in 53 of the selected studies. Of those, 39 analyzed factors associated with grief reactions. Six articles used PGS scores to evaluate pre- and post-bereavement interventions. Studies in English language only might have limited the number of articles.Significance of results: The PGS is the most used standardized measures to assess grief after perinatal loss. All parents living through any kind of perinatal loss should be screened.


  • Design, synthesis, biological activity and structure-activity relationship studies of chalcone derivatives as potential anti-Candida agents

    by Jéssica T. Andrade, Felipe R. S. Santos, William G. Lima, Carla D. F. Sousa, Lohanna S. F. M. Oliveira, Rosy I. M. A. Ribeiro, Ana J. P. S. Gomes, Marcelo G. F. Araújo, José A. F. P. Villar, Jaqueline M. S. Ferreira

    Vulvovaginal candidiasis (VVC) affects millions of women around the world every year. Candida albicans is the most frequently isolated pathogen in women and its rapid ability to develop resistance to first and second line therapies has boosted the search for new and effective antifungal agents. In this study, we show the in vitro anti-Candida activity of fifteen synthetic chalcone analogs and their antifungal potential in an in vivo model of VVC. Chalcone 12 showed potent antifungal effects, being able to inhibit the growth of Candida spp. at a concentration of 15.6 µg mL−1. In addition, mechanism of action studies have indicated the ergosterol fungal membrane as the target of this compound. Despite a considerable antifungal activity, the chalcone 12 showed high cytotoxicity in kidney cells lineages. Moreover, this compound was able to reduce Candida-associated virulence, impairing yeast–hyphal transition in C. albicans. An in vivo model of VVC showed that chalcone 12 significantly reduces the fungal load. Taken together, these findings showed that the chalcone 12 is a potent anti-Candida agent in vitro beyond of contribute to improve the fungal infection in a model of CVV. However, it showed low selectivity and high toxicity, suggesting molecular modifications to minimize these proprieties.